Previous preclinical studies have relied on MAPK or Akt activity, representing preserved functional signals from EGFR activation, as a parameter of tumour response to gefitinib treatment (Moasser et al, 2001; Moulder et al, 2001; Ono et al, 2004). This evidence concerns the gene EGFR and neoplasm.